Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Eli Lilly's stock price exceed $600 by end of 2024?
Yes • 50%
No • 50%
Closing stock price of Eli Lilly on a publicly available financial platform like Yahoo Finance or Bloomberg
Eli Lilly Cuts Zepbound Price by 50%, Impacting Hims Stock and Earning Biden's Praise
Aug 27, 2024, 03:28 PM
Eli Lilly has announced a significant price reduction for its weight-loss drug Zepbound, now offering single-dose vials at a 50% discount. This move aims to expand access to the drug, particularly for patients without insurance coverage. The discounted vials are available through Lilly's direct-to-consumer platform, LillyDirect, with prices set at $399 for a four-week supply of the 2.5 mg dose and $549 for the 5 mg dose. This initiative is part of Eli Lilly's strategy to address supply shortages and increase the availability of Zepbound amid rising demand. The price cut poses a challenge to telehealth companies that offer compounded versions of the medication. In response to the announcement, shares of Hims & Hers Health fell, reflecting the competitive impact of Lilly's strategy. Additionally, President Biden praised the price reduction as a positive step towards making medications more affordable.
View original story
Below $900 • 25%
$900 to $950 • 25%
$950 to $1000 • 25%
Above $1000 • 25%
Less than $500 • 25%
$500 to $600 • 25%
$600 to $700 • 25%
More than $700 • 25%
Less than $400 • 25%
$400 to $450 • 25%
$450 to $500 • 25%
More than $500 • 25%
No significant change in patient access • 25%
Significant increase in patient access • 25%
Decrease in patient access • 25%
Moderate increase in patient access • 25%
No significant change • 25%
Eli Lilly loses market share • 25%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%